The global hepatitis C virus treatment market was valued at USD 6.10 billion in 2025 and is projected to reach USD 8.01 billion by 2035, growing at a compound annual growth rate of 2.76%. While North America is expected to grow the fastest during the forecast period, the Asia-Pacific region is set to generate the largest revenue during the forecast period.
North America Expands Fastest While Asia-Pacific Generates Largest Revenue
The hepatitis C treatment market in North America is anticipated to experience the highest growth rate during the forecast timeframe, driven by the well-developed healthcare infrastructure in the United States, widespread availability of antiviral therapies, and state-backed initiatives centered around screening and care.
Global demand is further shaped by international health directives. In April 2026, the World Health Organization published its Global Hepatitis Report, urging nations to broaden prevention, screening, and care efforts in order to meet the elimination goals set for 2030. These policy objectives align with national financial commitments, exemplified by the July 28, 2025 declaration from the United States Department of Health and Human Services allocating $100 million toward Hepatitis C care, screening, and prevention for vulnerable populations, including individuals experiencing homelessness, severe mental illness, and substance use challenges.
Direct-Acting Antivirals and Shorter Regimens Drive Clinical Shifts
Therapeutic approaches rely heavily on direct-acting antivirals, which cure over 95% of patients by targeting the virus directly. Treatment durations have shortened significantly, with many patients completing treatment in 8 to 12 weeks. Major pharmaceutical manufacturers supply these regimens globally. Gilead Sciences, founded in 1987 and headquartered in Foster City, California, distributes medications such as Epclusa and Vosevi. AbbVie, based in North Chicago, Illinois, produces MAVYRET, an antiviral approved by the U.S. Food and Drug Administration in June 2025 and the European Commission in June 2026 for acute hepatitis C in adults and children aged three years and older.
Additional market participants include Merck & Co., which markets ZEPATIER for specific chronic infections, alongside Bristol Myers Squibb, Roche, Johnson & Johnson, Vertex Pharmaceuticals, Cipla, Mylan, and Dr. Reddy’s Laboratories. The development of affordable generic HCV medicines has simultaneously reduced medicine costs, supporting efforts to expand treatment access.
Global Hepatitis Treatment Market Dimensions
| Market Metric | Figure |
|---|---|
| Estimated Market Size (2025) | USD 6.10 Billion |
| Projected Market Size (2035) | USD 8.01 Billion |
| Compound Annual Growth Rate (2026–2035) | 2.76% |
| Fastest-Growing Region | North America |
| Largest Revenue Region | Asia-Pacific |
Frequently Asked Questions About Hepatitis C Market Dynamics
What factors drive the rapid market expansion in the North America region?
Growth in the United States is propelled by robust medical infrastructure, widespread availability of antiviral medications, and public initiatives dedicated to screening and therapeutic interventions.
How do direct-acting antivirals alter patient care timelines?
Modern direct-acting antivirals achieve cure rates exceeding 95% and shorten treatment courses, with many patients completing treatment in 8–12 weeks.
What regulatory approvals expanded pediatric and acute treatment options recently?
The U.S. Food and Drug Administration approved MAVYRET for acute hepatitis C in June 2025, followed by European Commission approval in June 2026 for acute hepatitis C in adults and children aged three years and older.
Related reading